Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,636
datasets available to search
ShareScore release 0.9.0
Dataset results
1,636 results for “Head and neck cancer;”
Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine
ClinicalTrials.gov study NCT01288625. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Genome-wide Scan for Methylation Profiles in head and Neck Cancer
GEO Series GSE67114. Homo sapiens. 8 samples. Type: Methylation profiling by genome tiling array.
Mapping EGFR-mediated local invasion and response to Cetuximab in head and neck cancer
GEO Series GSE273463. Homo sapiens. 40 samples. Type: Expression profiling by high throughput sequencing.
Identification of genes with altered expression in head and neck cancer
GEO Series GSE83519. Homo sapiens. 44 samples. Type: Expression profiling by array.
Analysis of microRNAs expression in four head and neck cancer cell lines
GEO Series GSE115000. Homo sapiens; Mus musculus; Rattus norvegicus. 4 samples. Type: Expression profiling by array.
In vivo CRISPR screens in Head and Neck Cancer reveal that Uchl5 modulates extracellular matrix deposition to promote immune evasion
GEO Series GSE269446. Mus musculus. 23 samples. Type: Expression profiling by high throughput sequencing.
Molecular subtypes of head and neck cancer – Prognostic impact and correlations with morphological characteristics
GEO Series GSE212070. Homo sapiens. 103 samples. Type: Expression profiling by array.
Expression profiling of invasion associated molecules in head and neck cancer cells
GEO Series GSE143689. Homo sapiens. 12 samples. Type: Expression profiling by array.
Gene expression in cancerous and paraneoplastic tissues of patients with head and neck squamous cell carcinoma.
GEO Series GSE228393. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing; Non-coding RNA profiling by high throughput sequencing.
4C-seq of HPV(+) head and neck cancer cell lines
GEO Series GSE211280. Homo sapiens. 4 samples. Type: Other.
Cetuximab resistant or sensitive head and neck cancer samples
GEO Series GSE36790. Homo sapiens. 10 samples. Type: Genome variation profiling by SNP array.
Dataset related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"
<p>This record contains raw data related to article "Adaptive Volumetric-Modulated Arc Radiation Therapy for Head and Neck Cancer: Evaluation of Benefit on Target Coverage and Sparing of Organs at Risk"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Radiotherapy is essential in the management of head-neck cancer. During the course of radiotherapy, patients may develop significant anatomical changes. Re-planning with adaptive radiotherapy may ensure adequate dose coverage and sparing of organs at risk. We investigated the consequences of adaptive radiotherapy on head-neck cancer patients treated with volumetric-modulated arc radiation therapy compared to simulated non-adaptive plans: Materials and methods: We included in this retrospective dosimetric analysis 56 patients treated with adaptive radiotherapy. The primary aim of the study was to analyze the dosimetric differences with and without an adaptive approach for targets and organs at risk, particularly the spinal cord, parotid glands, oral cavity and larynx. The original plan (OPLAN) was compared to the adaptive plan (APLAN) and to a simulated non-adaptive dosimetric plan (DPLAN).</p><p><strong>Results: </strong>The non-adaptive DPLAN, when compared to OPLAN, showed an increased dose to all organs at risk. Spinal cord D2 increased from 27.91 (21.06-31.76) Gy to 31.39 (27.66-38.79) Gy (<i>p</i> = 0.00). V15, V30 and V45 of the DPLAN vs. the OPLAN increased by 20.6% (<i>p</i> = 0.00), 14.78% (<i>p</i> = 0.00) and 15.55% (<i>p</i> = 0.00) for right parotid; and 16.25% (<i>p</i> = 0.00), 18.7% (<i>p</i> = 0.00) and 20.19% (<i>p</i> = 0.00) for left parotid. A difference of 36.95% was observed in the oral cavity V40 (<i>p</i> = 0.00). Dose coverage was significantly reduced for both CTV (97.90% vs. 99.96%; <i>p</i> = 0.00) and PTV (94.70% vs. 98.72%; <i>p</i> = 0.00). The APLAN compared to the OPLAN had similar values for all organs at risk.</p><p><strong>Conclusions: </strong>The adaptive strategy with re-planning is able to avoid an increase in dose to organs at risk and better target coverage in head-neck cancer patients, with potential benefits in terms of side effects and disease control.</p>
Dataset related to article "Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer"
<p><strong> Abstract</strong></p><p>Background: Prediction of survival and radiation therapy response is challenging in head and neck cancer with metastatic lymph nodes (LNs). Here we developed novel radiomics- and clinical-based predictive models.</p><p>Methods: Volumes of interest of LNs were employed for radiomic features extraction. Radiomic and clinical features were investigated for their predictive value relatively to locoregional failure (LRF), progression-free survival (PFS), and overall survival (OS) and used to build multivariate models.</p><p>Results: Hundred and six subjects were suitable for final analysis. Univariate analysis identified two radiomic features significantly predictive for LRF, and five radiomic features plus two clinical features significantly predictive for both PFS and OS. The area under the curve of receiver operating characteristic curve combining clinical and radiomic predictors for PFS and OS resulted 0.71 (95%CI: 0.60-0.83) and 0.77 (95%CI: 0.64-0.89).</p><p>Conclusions: Radiomic and clinical features resulted to be independent predictive factors, but external independent validation is mandatory to support these findin</p>
Phase I clinical trials landscape for patients with head and neck cancers in a tertiary referral centre
Open the record for dataset details and reuse information.
Targeting PLK1 with Onvansertib and Radiation in Head and Neck Cancer
GEO Series GSE306710. Homo sapiens. 24 samples. Type: Expression profiling by high throughput sequencing.
Expression analysis of radio-resistant and -sensitive head and neck cancer cells
GEO Series GSE217645. Homo sapiens. 33 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.